Ratings by Roth/MKM (Boobalan Pachiyappan)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/23/2026 | Cingulate | CING | Maintain | Buy (N/A) |
|
Details | ||
| 7/10/2025 | Verona Pharma | VRNA | Downgrade | Neutral (Buy) |
86.86 (106.91) |
23.08% | Details | |
| 1/10/2025 | Verona Pharma | VRNA | New Coverage | Buy (N/A) |
49.55 (86.86) |
75.3% | Details | |
| 1/10/2025 | Cingulate | CING | New Coverage | Buy (N/A) |
4.70 (4.83) |
2.77% | Details |
